Starpharma expects $4.7m R&D tax rebate
15 January, 2014 by Dylan Bushell-EmblingFollowing a positive AusIndustry decision on overseas R&D, Starpharma (ASX:SPL) expects to receive a $4.7 million rebate this financial year for development work conducted during FY13.
STA to distribute breast cancer test in Australia
14 January, 2014 by Dylan Bushell-EmblingSpecialised Therapeutics Australia (STA) has clinched a deal to become the Australian distributor for Oncotype DX, a genomic test used to inform treatment strategies for breast cancer patients.
Viralytics hits recruitment target for cancer trial
09 January, 2014 by Dylan Bushell-EmblingViralytics (ASX:VLA) has reached its 54-patient recruitment target for a US phase II trial of its Cavatak cancer treatment in malignant late-stage melanoma.
Bioniche names new COO
09 January, 2014 by Dylan Bushell-EmblingDonald Olds has joined Bioniche (ASX:BNC) as COO, to help guide the company through the sale of its animal health business and help it meet its oncology ambitions.
Sports supplement helps fight type 2 diabetes
09 January, 2014Research at Southern Cross University (SCU) has found that a popular sports supplement may help in the fight against type 2 diabetes.
A final note for 2013
12 December, 2013As Christmas celebrations sneak around the corner, we write our final newsletter for the year.
Advancing bowel cancer research
11 December, 2013Bowel cancer research has received a $15 million gift.
Starpharma company secretary retires this week
10 December, 2013 by Dylan Bushell-EmblingStarpharma (ASX:SPL) CFO Nigel Baade will take on the responsibilities of company secretary Ben Rogers who is retiring, effective from Friday.
Ascend, 3M team for cancer vaccine research
09 December, 2013 by Dylan Bushell-EmblingAscend Biopharmaceuticals has entered an agreement with 3M Drug Delivery Systems to evaluate conjugating a 3M agonist with Ascend's ASN cancer vaccine platform.
Biotron's BIT225 can clear out HIV reservoir pools
06 December, 2013 by Dylan Bushell-EmblingNew data from a Biotron (ASX:BIT) study of its BIT225 drug candidate suggest it can reduce the quantity of virus in HIV reservoir cells as well as stopping HIV replication.
GTG's breast cancer risk test is cost-effective
06 December, 2013 by Dylan Bushell-EmblingA virtual trial of Genetic Technologies' (ASX:GTG) BREVAGen genetic test for breast cancer risk shows it is most cost-effective in women with an intermediate risk.
Big congresses down under
03 December, 2013Australia appears to have reached tipping point and is starting to attract large international congresses bringing thousands of delegates to our shores.
Minomic seeks to set prostate cancer test standard
02 December, 2013 by Dylan Bushell-EmblingSydney biotech Minomic aims to commercialise a new prostate cancer test in Australia in 2015-16 and hopes it will become the new diagnostic standard within five years.
Alchemia cleared to continue HA-Irinotecan trial
02 December, 2013 by Dylan Bushell-EmblingThe DSMB monitoring Alchemia's (ASX:ACL) phase III trial of HA-Irinotecan in metastatic colorectal cancer has, for the fourth time, recommended that the trial continue.
New treatment for osteoporosis
28 November, 2013A compound that stimulates bone formation in animal models holds promise as a new type of medicine for osteoporosis.
